About: Mirjam Zeisel

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mirjam Zeisel Goto Sponge NotDistinct Permalink

An Entity of Type : foaf:Person, within Data Space : data.idref.fr associated with source document(s)

Attributes	Values
type	Person
sameAs	Zeisel, Mirjam (1976-....) Zeisel, Mirjam (1976-....) Zeisel, Mirjam (1976-....) Zeisel, Mirjam (1976-....)
Life Event	http://www.idref.fr/092626475/birth
preferred label	Zeisel, Mirjam (1976-....)
name	Mirjam Zeisel
dbpedia-owl:citizenship	http://sws.geonames.org/2921044/
Language	http://lexvo.org/id/iso639-3/fra http://lexvo.org/id/iso639-3/deu
isni:identifierValid	0000000357287148
Given name	Mirjam
familyName	Zeisel
has biographical i...tion (Deprecated)	Titulaire d'un Doctorat de Aspects Moléculaires et Cellulaires de la Biologie.Immunopharmacologie (Strasbourg 1, 2004) Chargée de recherche à l’Inserm depuis 2008, Mirjam Zeisel co-dirige le groupe thématique Baumert-Zeisel à l’Institut de recherche sur les maladies virales et hépatiques (UMR_S1110) (Strasbourg) (2019) Chargée de recherche à l'Inserm, membre du Centre de Recherche en Cancérologie de Lyon (en 2021)
gender	female
ORCID iD	0000-0003-1606-0131
org:hasMembership	http://www.idref.fr/092626475/affiliation/2 http://www.idref.fr/092626475/affiliation/1
org:memberOf	Université de Strasbourg (2009-....) Institute for Translational Medicine and Liver Disease (Strasbourg ; 201.-....)
Scopus ID	6506357429
is sameAs of	Zeisel, Mirjam (1976-....) Zeisel, Mirjam (1976-....) Zeisel, Mirjam (1976-....) Zeisel, Mirjam (1976-....) Zeisel, Mirjam (1976-....) Zeisel, Mirjam (1976-....)
is Thesis advisor of	http://www.sudoc.fr/196282713/id http://www.sudoc.fr/196776791/id http://www.sudoc.fr/248549405/id http://www.sudoc.fr/278481728/id
is Author of	http://www.sudoc.fr/147119448/id http://www.sudoc.fr/05371234X/id http://www.sudoc.fr/092626416/id Immunité innée et polyarthrite rhumatoïde, étude des interactions PAMPs-PRRs dans l'activation des synoviocytes \"fibroblast-like\" http://hub.abes.fr/edp/periodical/medsci/2015/volume_31/issue_12/medsci20153112p1075/w Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. http://www.sudoc.fr/246846283/id Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles. Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes using monoclonal antibodies. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. miR-122-regulated metabolic circuits: micro-management of lipid metabolism in the human liver HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse Model Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription Neutralizing antibodies in hepatitis C virus infection. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. http://hub.abes.fr/edp/periodical/medsci/2011/volume_27/issue_11/medsci20112711p929/w Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis Host neutralizing responses and pathogenesis of hepatitis C virus infection. Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity The lncRNAs in HBV-Related HCCs: Targeting Chromatin Dynamics and Beyond Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma Development of hepatitis C virus vaccines: challenges and progress. A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity Tight junction proteins in gastrointestinal and liver disease Interleukin-32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance Production of infectious hepatitis C virus in tissue culture: a breakthrough for basic and applied research. MMP-3 expression and release by rheumatoid arthritis fibroblast-like synoviocytes induced with a bacterial ligand of integrin alpha5beta1. Clinical development of hepatitis C virus host-targeting agents Getting closer to the patient: upgrade of hepatitis C virus infection in primary human hepatocytes. Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Anticorps neutralisants dirigés contre le virus de l’hépatite C Characterization of Hepatitis C Virus Particle Subpopulations Reveals Multiple Usage of the Scavenger Receptor BI for Entry Steps Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment Opening the door for hepatitis C virus infection in genetically humanized mice. Reconstitution of the entire hepatitis C virus life cycle in non-hepatic cells. https://hal.archives-ouvertes.fr/hal-02460232#id HCV entry and neutralizing antibodies: lessons from viral variants. Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma Plasmodium P36 determines host cell receptor usage during sporozoite invasion [Open Sesame: regulation of hepatitis C virus entry into hepatocytes]. https://archive-ouverte.unige.ch/unige:166503#id Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes. Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus–Infected Cells and Liver to Identify Pathways Associated With Disease Development

Faceted Search & Find service v1.13.91 as of Aug 16 2018

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software